News

LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth

The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® Read more...

Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer

SALT LAKE CITY, May 17, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that Nadia F. Altomare has joined the company as Read more...

Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada

Princess Margaret Cancer Centre to initiate a 20-patient pilot study to assess hydrogel spacer to reduce rectal toxicity during prostate cancer radiation Read more...

Sera Prognostics is Named a 2017 Silver Edison Award Winner

PreTRM® Test Wins at New York Ceremony; Awards Celebrate 30 Years of Honoring Innovators and Innovation NEW YORK, April 21, 2017 (GLOBE NEWSWIRE) -- Read more...

Research on Fetal Sex Differences in Predicting Spontaneous Preterm Birth Using Sera’s Proteomic Technology to be Presented at The 64th Annual Society for Reproductive Investigation Meeting

SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that research using Sera’s Read more...

Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Sera Prognostics’ PreTRM® Named Edison Awards Finalist

PreTRM® to be Recognized at Edison Awards Gala on April 20, 2017 in New York SALT LAKE CITY, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, a women’s Read more...

SERA PROGNOSTICS ENTERS INTO AGREEMENT WITH LABCORP TO BE THE EXCLUSIVE U.S. DISTRIBUTOR OF PRETRM® TEST

SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth Sera Prognostics, Read more...

Page 1 of 27123...Last »

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184